Breast cancer remains a leading cause of cancer death among women worldwide, particularly in low-resource regions where access to advanced diagnostics is limited. Emerging research highlights the growing role of inexpensive blood-based markers in detecting, monitoring, and predicting outcomes in breast cancer.
Blood Counts Reveal Immune and Inflammatory Clues
Routine hematological tests, such as complete blood counts (CBC), offer insights into systemic inflammation and immune response—key factors in cancer progression.
Red and white blood cells: Patients often show reduced hemoglobin and red blood cell counts, signaling anemia. White blood cell populations, including lymphocytes, neutrophils, and monocytes, also differ significantly from healthy individuals.
Neutrophil-to-lymphocyte ratio (NLR): Elevated NLR correlates with poorer prognosis, including shorter disease-free and overall survival, especially in HER2-positive and triple-negative breast cancers.
Platelet-to-lymphocyte ratio (PLR): Higher PLR is associated with aggressive tumors, lymph node involvement, and elevated tumor grade.
Erythrocyte sedimentation rate (ESR): Elevated ESR, a general inflammation marker, is linked to worse outcomes.
Biochemical Markers Track Tumor Activity
Serum-based biochemical markers complement hematological data by reflecting metabolic changes and organ involvement.
Enzymes: High lactate dehydrogenase (LDH) levels indicate tumor progression and metastasis. Alkaline phosphatase (ALP) often signals bone or liver involvement.
Creatine kinase-BB (CK-BB): May indicate hormone-dependent tumor activity.
Serum uric acid (SUA): Shows a complex, J-shaped relationship with breast cancer risk, acting as both antioxidant and pro-inflammatory agent.
C-reactive protein (CRP): Elevated CRP reflects systemic inflammation and correlates with tumor burden.
Cancer antigens (CA 15-3, CA 27.29): Reliable for monitoring treatment response, recurrence, and metastasis.
D-dimer: Higher levels suggest advanced disease and tumor-induced coagulation.
Oxidative stress markers: Elevated reactive oxygen species (ROS) and reduced antioxidant enzymes such as catalase indicate tumor-associated oxidative stress.
Integrating Biomarkers Into Patient Care
No single marker offers definitive early detection. However, combining hematological and biochemical indicators improves risk assessment, prognostic accuracy, and treatment monitoring. Integrating NLR and PLR with tumor immune profiles enhances prediction of outcomes. Limitations include low specificity and influence from non-cancer conditions such as infection or obesity. These markers are most effective when used alongside imaging and clinical evaluation.
Conclusion
Hematological and serum biomarkers offer a cost-effective, non-invasive approach to breast cancer management. Markers such as NLR, PLR, CA 15-3, and oxidative stress indicators provide actionable insights into tumor behavior and prognosis. Integrating these markers into multi-modal diagnostic strategies could support earlier detection, personalized treatment, and more equitable care worldwide.
Related topics
PEG Hydrogel May Reduce Rectal Damage in Cervical Cancer Treatment
AI Benchmark Brings Visual Question Answering to Mammogram Diagnostics
Plastic Surgery Practice Defyne Blends Global Expertise with Personalized Care
